Renhe Group and APR Applied Pharma Research Announce a License Agreement for the Distribution in the Chinese Market of an Innovative Solution to Treat Migraine
APR Applied Pharma Research s.a. (“APR”), the Swiss, independent developer of science driven, patent protected healthcare products, and Renhe Group, a Chinese leading pharmaceutical company, today are proud to announce the start of a partnership for the promotion, distribution and marketing of APR’s patented Diclofenac powder for oral solution for migraine treatment, in China, Hong Kong, Macao and Taiwan.
Migraine prevalence in China is rapidly growing due to the increasing population of patients affected in combination with the swift change of the society towards a modern industrialized country lifestyle, thus making the anti-migraine drugs market potential attractive.
The current market size for specific anti-migraine preparations is still very limited in China, accounting for around 1 mio USD, as disease awareness amongst patients and doctors is scarce and differentiated diagnosis is still very limited; however, its growth rate is significant (+117%) as underdiagnoses reduces. Moreover, the main drugs available specific for migraine therapy are standard triptans (either branded or generics), thus leaving unaddressed the need of a fast effective and tolerable treatment.
APR’s unique and exclusive formulation of Diclofenac, based on the APR’s patented Dynamic Buffering Technology (“DBT”),is particularly suitable for the management of migraine, by securing faster pain relief, rapid onset of action and sustained pain-free, thus reducing recurrence of migraine attacks associated with a favourable side-effect profile and projecting this product to be the first NSAID specifically approved for migraine in China, thus replicating the same success story APR was able to achieve in the USA.
“With this agreement, Renhe Group aims to seize this market opportunity by fulfilling the need for a specific fast acting and tolerable migraine treatment. At the same time, this innovative and proven solution perfectly matches the current increasing demand for Western-type therapies in China. We are confident that adding this drug to our portfolio will help us to successfully position Renhe Group as reference company in the migraine market.”- states Mr Chunyu Li, Renhe Group General Manager.
“We are proud of this new agreement, which allows us to enter dynamic markets with the highest population rate worldwide, like China, Macao and Hong Kong. We believe this partnership will offer great business opportunities to an European based company like APR as well as to our local partner Renhe Group- said Paolo Galfetti, Chief Executive Officer of APR -APR’s Diclofenac drugs, including DBT based ones, are currently marketed and promoted in several countries all over the world, thanks to a wide network of partners, such as Novartis AG and Depomed.
Approximately 100 million doses of APR’s Diclofenac DBT are sold every year, confirming the distinctive and exclusive competitive advantage of APR’s formulation over conventional preparations.”
About Diclofenac Powder for Oral Solution
APR’s Diclofenac powder for oral Solution is based on APR’s patented Dynamic Buffering Technology (DBT): this exclusive technology includes a unique blend of Diclofenac and bicarbonate that creates a suitable microenvironment at gastrointestinal level, avoiding precipitation of acid Diclofenac in the gastric environment and, thus, allowing a fast absorption, without affecting overall tolerability and safety of the drug product. Pharmacokinetic data support its positive results in terms of an immediate and ready absorption in the gastro-intestinal tract, hence achieving a faster onset of action.
As shown in clinical trials on migraine patients(1,2,3,4), APR’s Diclofenac powder for oral solution consistently provides a rapid relief from multiple migraine symptoms (nausea, photophobia, phonophobia) in 2 hours by starting to work in just 15 minutes - at achievement of peak plasma levels-as well as a pain-free response lasting up to 24 hours, by targeting effectively inflammation. On the other hand, it comes in a convenient water-soluble formulation and has a favorable and tolerable side-effect profile, similar to placebo.
Moreover, Diclofenac powder for oral solution has been recently established as “effective” (Level A) for the therapy of acute migraine attacks by the AHS (America Headache Society), following an evidence-based assessment via a systematic review of Class I studies (www.apr.ch/news/new-patent-for-aprs-diclofenac-formulation-in-canada).
1. Diener HC, Montagna P, Gács G, et al. Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia. 2006;26(5):537-547. 2. Lipton RB, Grosberg B, Singer RP, et al. Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia. 2010;30(11):1336-1345. 3. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629-808. 4. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20.
About APR – APPLIED PHARMA RESEARCH
APR is a Swiss, independent developer of science driven, patent protected healthcare products. The Company identifies, develops and licenses, value added products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis. In particular, APR’s business model is currently focused on two pillars: (i) internally developed and financed (alone or together with co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets, combined with a compelling pipeline of products at different stages of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries, with international sales on a worldwide basis.
For press releases and other company information, please visit: www.apr.ch
Renhe pharmaceutical Bioengineering Co. Ltd., established in 2008, is a GSP certified pharmaceutical sales organization with a distribution network cross the nation. The company main focus is on chemical compounds for prescription drugs and traditional Chinese products for OTC market. The company now has regional office in Beijing, Shanghai, and Hangzhou with total revenue over 200 million RMB in 2015
For press releases and other company information, please visit: www.renhe.com
PAOLO GALFETTI, Tel: +41 91 695 70 20
Chunyu Li, Tel:+86 22 8639 2936
HAVAS PR MILAN:
SARA BERNABOVI, T: +39 02 85457032
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Technics Organizes World's First Full Turntable Orchestra20.3.2018 14:48 | Pressemelding
On March 20, 2018, the "Record Day," Panasonic Corporation released the video of the world's first full orchestra performance featuring Technics "turntables (analog record players)" as the only instruments, under the Technics brand's theme, "Rediscover Music." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180320006023/en/ World's First Full Turntable Orchestra organized by Technics (Photo: Business Wire) Videos: - THE PHILHARMONIC TURNTABLE ORCHESTRA https://youtu.be/JGWuyMKT8wU - BEHIND THE BEATS : THE PHILHARMONIC TURNTABLE ORCHESTRA https://youtu.be/J2KK3vqJqog "The Philharmonic Turntable Orchestra" special website Thirty renowned DJs from around the world, including DJ Rena, the reigning Japanese world champion (youngest ever world champion in history), who took the "DMC World Championship" title in 2017 at just 12 years old*, came together to create the world's first "turntable orchestra." Using the Technics' iconic tu
Bentley Systems' Year in Infrastructure 2018 Conference and Awards Gala to be Held in London, Oct. 15-1820.3.2018 14:30 | Pressemelding
Bentley Systems, Incorporated, a leading global provider of comprehensive software solutions for advancing infrastructure, today announced that the Year in Infrastructure 2018 Conference will be held Oct. 15 through 18 in London at the Hilton London Metropole. Presented by Bentley Institute, the conference is a global gathering of leading industry executives and prominent thought leaders in the design, construction, and operations of the world’s infrastructure. The theme of this year’s conference is Going Digital: Advancements in Infrastructure. The conference features nearly 70 speakers and more than 50 informative sessions, including keynotes by leading industry experts, interactive workshops, forums, panel discussions, and product demonstrations. Attendees can visit the Technology Pavilion, which features exhibits and presentations from Bentley Systems and its strategic partners Microsoft, Siemens, Topcon, and Bureau Veritas. On the first day of the conference, Bentley Institute wil
Chargebee Closes Series C with $18 Million Investment from Insight Venture Partners20.3.2018 13:30 | Pressemelding
Chargebee, a SaaS subscription management and recurring billing solution, has secured $18 Million in growth capital, led by New York-based Insight Venture Partners. The Series C investment also saw participation from previous investors, Accel Partners and Tiger Global Management. With this round of funding, the total investment stands at $24.7 Million. This capital will be used for increased investment in product R&D, sales, marketing and growth, to expand aggressively into newer markets and segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180320005567/en/ Chargebee founders (Photo: Business Wire) Chargebee offers a payment gateway agnostic subscription billing solution, complementing gateways like Stripe, Braintree, PayPal, Adyen and many others. Chargebee powers the recurring revenue engines of B2B and B2C services across various industry verticals like SaaS, Digital Media, eCommerce, and IoT. Founded in 2011, Char
Signalhorn Selects LeoSat for Next-Generation Data Network20.3.2018 13:03 | Pressemelding
LeoSat Enterprises, which is launching a constellation of up to 108 low-earth-orbit communications satellites, has entered into an agreement with Signalhorn, a leading provider of hybrid network solutions for Enterprise and Government customers worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180320005849/en/ LeoSat Data Network Constellation (Graphic: Business Wire) With the ever-growing demands of managing Big Data and Cybersecurity, global enterprises and governments now, more than ever, need instant infrastructure from anywhere to everywhere which is fast, secure and reliable. LeoSat’s system of low earth orbit communications satellites can achieve lower latency and stronger end-to-end security compared to traditional satellite and terrestrial solutions used today. This is achieved through an advanced and unique system architecture utilizing optical inter-satellite laser links which connect the satellites, creat
Magento Commerce Investment in Europe Accelerates Growth20.3.2018 12:57 | Pressemelding
Magento Commerce, the worldwide leader in cloud digital commerce innovation, today announced more than 100 percent growth in new B2B and B2C customers in Europe. The company’s strong momentum is a result of continued investment in the region, expansion of its global partner ecosystem, and the platform’s ability to empower merchants with the flexibility needed to deliver highly differentiated customer experiences. Today, over 60 percent of merchants on Magento Commerce operate hybrid B2B/B2C and B2B2C models. Organisations are increasingly seeing the business benefits of cloud platforms and solutions, with 88 percent of UK organisations adopting cloud last year, according to the Cloud Industry Forum (CIF). Magento Commerce Cloud represented over 40 percent of the company’s new licenses in 2017 and is the platform of choice for customers of all sizes, including Christian Louboutin and Big Bus Tours. Additionally, the expansion of the Magento ecosystem of developers and partners has helpe
Advantis Medical Imaging Receives CE Mark for Brainance® MD, its Cloud-Based Neuroimaging Software.20.3.2018 11:00 | Pressemelding
Advantis Medical Imaging announces that it received CE Mark approval for Brainance ® MD, its Cloud-Based Neuroimaging software. This market approval allows Brainance ® MD to be used as part of the clinical workflow for the advanced processing of Brain MR images. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180320005408/en/ “We feel really excited to make this announcement. This is a significant milestone for our company and the fact that Brainance ® MD can now be integrated in the clinical processing workflow fulfills one of Advantis principal goals: to make state-of-the-art processing methodologies available for every doctor, anywhere, anytime. ” said Zoi Giavri, CEO and co-founder of Advantis Medical Imaging. “This CE Mark approval confirms our capacity for innovation and justifies the entire team’s devotion and effort on striving for increased quality and performance, while bringing added value to the daily clinical pra